Esophageal cancer is diagnosed primarily through upper endoscopy with biopsy, a procedure that takes 5 to 20 minutes and allows a doctor to visually examine the esophagus and collect tissue samples. That tissue is then analyzed under a microscope to confirm whether cancer cells are present. If cancer is confirmed, additional imaging and ultrasound tests determine how far it has spread, which shapes the entire treatment plan.
Upper Endoscopy and Biopsy
The first and most important step is an upper endoscopy, sometimes called an EGD. A gastroenterologist passes a thin, flexible tube with a camera and light on its tip through your mouth, down the esophagus, and into the stomach. Air is gently pushed through the tube to expand the area and give a clearer view of the lining. The doctor examines the tissue directly on a screen and can spot abnormal patches, masses, or narrowing.
When anything looks suspicious, the doctor takes biopsies through the scope, snipping small tissue samples that are sent to a pathology lab. This is the only way to confirm esophageal cancer. In clinical practice, upper endoscopy detects esophageal cancer with a sensitivity of about 91% over a two-year window and roughly 95% within one year, meaning it catches the vast majority of cases but a small number can be missed, particularly very early lesions.
You’ll receive sedation through an IV beforehand, so you’re relaxed but not fully asleep. You lie on your left side, and your heart rate, blood pressure, and oxygen levels are monitored throughout. Most people don’t remember much of the procedure and go home the same day, though you’ll need someone to drive you.
What Pathologists Look For
Once the biopsy reaches the lab, a pathologist examines the cells under a microscope to determine two things: whether cancer is present and, if so, what type it is. The two main types are squamous cell carcinoma, which develops from the flat cells lining most of the esophagus, and adenocarcinoma, which arises from gland-like cells typically found near the junction where the esophagus meets the stomach. The distinction matters because these cancers behave differently and may respond to different treatments.
If cancer is confirmed and has spread or is suspected of spreading, pathologists run additional biomarker tests on the tissue. Two are especially important for guiding treatment. The first checks whether the tumor overproduces a protein called HER2, which makes it a target for specific drugs. The second measures a protein called PD-L1, which helps determine whether immunotherapy could be effective. Both tests are standard when metastatic disease is documented or suspected.
Endoscopic Ultrasound for Tumor Depth
Knowing that cancer exists isn’t enough. Doctors need to know how deep the tumor has grown into the esophageal wall and whether nearby lymph nodes are involved. This is where endoscopic ultrasound (EUS) comes in. The procedure looks similar to a standard endoscopy, but the scope has an ultrasound probe on its tip that sends sound waves into the tissue and creates detailed images of the esophageal wall layers.
EUS can distinguish the individual layers of the esophageal wall, which lets doctors determine whether a tumor is still superficial or has grown into deeper muscle and surrounding tissue. This distinction directly affects treatment. A tumor confined to the inner lining may be removable through the endoscope itself, while one that has grown through the wall typically requires surgery, often with chemotherapy beforehand.
EUS also reveals lymph nodes near the esophagus. Nodes that are round, smooth-edged, larger than 1 centimeter, and dark on ultrasound are more likely to contain cancer. But appearances alone aren’t definitive. The scope can also guide a fine-needle aspiration, inserting a thin needle into a suspicious lymph node to collect cells. Adding this needle sampling to the ultrasound raises the accuracy of lymph node staging from about 74% to 90%.
CT and PET Scans for Spread
Once the local picture is clear, imaging scans check whether the cancer has traveled to distant organs. A CT scan of the chest and abdomen provides detailed cross-sectional images that reveal enlarged lymph nodes, liver lesions, or lung nodules.
A PET/CT scan adds another layer. You receive an injection of a radioactive sugar that cancer cells absorb more readily than normal tissue. The scan then highlights areas of high metabolic activity throughout the body, making it easier to spot metastases that a CT alone might miss. PET/CT is particularly useful for evaluating lymph nodes. Studies show it has a negative predictive value between 88% and 98% for lymph node involvement, meaning that when the scan shows no activity in a node, it is very likely cancer-free.
Together, these scans help determine whether the cancer is still localized, has reached regional lymph nodes, or has spread to distant sites. That information is essential for deciding between curative treatment and palliative approaches.
How Staging Works
All the information from endoscopy, ultrasound, and imaging feeds into a staging system that uses three factors: how deep the tumor has grown (T), whether lymph nodes are involved (N), and whether there are distant metastases (M).
The tumor depth ranges from T1, where cancer is still in the inner layers of the esophageal wall, to T4, where it has invaded nearby structures like the airway, the sac around the heart, or even the aorta. Lymph node involvement is graded by the number of affected nodes: N1 means one or two, N2 means three to six, and N3 means seven or more. Distant metastasis is simply present (M1) or absent (M0). These three factors combine into an overall stage, from stage I (early, localized) to stage IV (spread to distant organs), which guides the treatment approach and gives the clearest picture of prognosis.
Screening Before Symptoms Appear
Most esophageal cancers are found after symptoms develop, such as difficulty swallowing, unintentional weight loss, or persistent chest pain. By that point, the disease is often advanced. Screening is not recommended for the general population, but it plays a role for people at higher risk.
People with Barrett’s esophagus, a condition where chronic acid reflux changes the cell lining of the lower esophagus, face an elevated risk of developing adenocarcinoma. A 2025 guideline from the American Gastroenterological Association recommends surveillance endoscopy every three years for patients with nondysplastic Barrett’s esophagus, using high-definition white light endoscopy combined with chromoendoscopy (a technique that applies dye to make abnormal tissue easier to see). For very short segments of changed tissue under 1 centimeter, the guideline recommends against routine surveillance, as the cancer risk is very low.
Researchers are also developing less invasive screening tools. One device, called the Cytosponge, is a small sponge on a string that you swallow in capsule form. Once the capsule dissolves, the sponge is pulled back up, collecting cells from the esophageal lining along the way. Those cells are analyzed for signs of abnormal growth and a protein called p53 that signals higher cancer risk. It has been piloted as an alternative to endoscopy for Barrett’s surveillance, though it is not yet part of standard clinical practice.